May 11, 2019 - 13:47 AMT
PanARMENIAN.Net - Nearly half of people with Alzheimer’s can’t sleep at night, waking up more often and staying awake longer than others their age. This causes nighttime wandering, and worsens cognition and depression. Despite the burden for both patient and caregiver, many physicians do not prescribe available hypnotics, sedatives, or antipsychotics for fear of causing falls, stroke, or hastening cognitive decline. Now, results of a Phase 3 trial testing Merck’s insomnia drug suvorexant, sold as Belsomra, in patients with mild to moderate AD, suggest that this drug prolongs slumber, with more overall sleep time and shorter bouts of nighttime wakefulness than placebo. The drug is FDA-approved for insomnia and has been reported safe in the elderly population. Merck scientists presented this data at the American Academy of Neurology’s 71st Annual Meeting, held May 4–10 in Philadelphia, Alzforum says.
“Clinicians often say they are hesitant to try suvorexant in AD patients because of insufficient data to support the efficacy and safety in this key subpopulation,” W. Joseph Herring, Merck, Kenilworth, New Jersey, who presented the results, told Alzforum. “We’ve shown that suvorexant was effective in improving sleep and generally well tolerated in patients,” he said.
“They did a really nice study,” said David Holtzman, Washington University in St. Louis. “It clearly shows the drug caused more sleep, and there was a pretty strong effect. I think it’s worth trying in some of our dementia patients with sleep problems.”
Suvorexant tablets are to be taken 30 minutes before bedtime. The drug targets orexin receptors in the brain. A neurotransmitter produced in the hypothalamus, orexin binds to receptors in several brain regions, and the ensuing signaling works to keep a person awake. By binding and blocking orexin receptors, suvorexant temporarily halts orexin signaling.
Some people with Alzheimer’s have high orexin levels in their cerebral spinal fluid, which is thought to contribute to the disturbance in their sleep/wake cycle (Gabelle et al., 2017). This is the first study to evaluate suvorexant in AD.
The 277 participants who completed the double-blinded trial averaged 70 years of age and scored between 12 and 26 on the Mini Mental State Examination (MMSE) when they enrolled. Eight participants dropped out. They all suffered from insomnia as defined by the DSM-IV, meaning they had enough trouble falling asleep or staying asleep to impair their daily functioning. All participants first got placebo for two weeks and spent two nights in a sleep lab to record a baseline sleep pattern. Then 136 were randomized to 10 mg suvorexant and 141 to placebo. After two weeks, 77 percent of treated patients tolerated the drug well enough to double their doses. Five mg, 10mg, and 20 mg tablets are FDA-approved. After four weeks, a final overnight polysomnography test assessed the impact of drug or placebo.
Suvorexant met both its primary and secondary efficacy endpoints, improving total sleep time and shortening wake time in the middle of the night. At baseline, people on drug slept an average of 278 minutes, similar to the 274 minutes for those on placebo. After four weeks of treatment, those on suvorexant snoozed 73 minutes longer at night while the placebo controls improved by 45 minutes, a 28-minute advantage for the drug. The 45 minutes more sleep in the non-drug group—a large placebo effect—was due to sleep hygiene coaching that was also part of the trial, Herring said. A 20-minute improvement is considered clinically meaningful, Herring said. Treated individuals were twice as likely as those on placebo to gain an hour of extra sleep.
After falling asleep, patients on the drug woke up and then lay awake in the middle of the night for 45 minutes less than they had at baseline. People on placebo reduced their wake time by 30 minutes, a 15-minute improvement for the drug. In addition, treated patients scored lower on the Clinician Global Impression of Severity (CGI-S) of insomnia versus placebo, while caregivers rated the patients’ sleep quality higher.
Herring said one concern about using sleep medications in dementia is that the drug might worsen cognition. The researchers assessed MMSE and the Digit Symbol Substitution test at baseline and after four weeks and saw no difference between scores. This was but a short-term trial. Merck did not present longer-term data on sleep or cognition.
Adverse events occurred in 22 percent of drug-treated patients, compared with16 percent of the placebo group. They included mild-to-moderate drowsiness during the day in six patients treated with suvorexant versus two people on placebo, headache in five treated and six controls, dry mouth in three treated patients and one on placebo, and falls in three from the treatment group.
“The absolute and placebo-relative improvements are quite dramatic, and hopefully reflect physiologically healthy sleep,” wrote Logan Schneider, Stanford University School of Medicine, California, to Alzforum. “The undesirable consequences of non-physiologic sleep that standard hypnotics or sedatives provide often make me quite cautious about using traditional medications in this population,” Schneider wrote. He was less concerned about the daytime drowsiness experienced by some patients, though he wondered about the duration of symptoms and impact on quality of life.
Merck plans to file the data with the FDA for potential inclusion in the BELSOMRA prescribing information.
Sleeplessness reportedly drives the accumulation of amyloid and release of tau (Jan 2018 news; Apr 2018 news; Jan 2019 news). Could suvorexant potentially slow disease progression by lengthening sleep? No longer-term studies are currently planned to explore this question, though it is on the radar for the future, Herring told Alzforum.
The possibility is intriguing, Holtzman agreed, saying, “Researchers might want to explore this mechanism as a prevention strategy, to see if we could actually delay the amyloid and tau-induced changes promoted by too much wakefulness.”
Suvorexant is also being studied for insomnia in multiple sclerosis, PTSD, and diabetes, as well as bipolar, major depressive, and alcohol and cocaine use disorders.